Keywords: وگت-کویانگی-هارادا; AE; adverse event; AS; ankylosing spondylitis; BCVA; best-corrected visual acuity; EL; evidence level; ISC; International Steering Committee; NCSIT; noncorticosteroid systemic immunomodulatory therapy; NIU; noninfectious uveitis; PsA; psoriatic arthritis;